ID   TR14
AC   CVCL_B474
SY   TR-14
DR   Cosmic; 1109113
DR   Cosmic; 1518080
DR   Cosmic; 1526657
DR   Cosmic; 2239466
DR   GEO; GSM692868
DR   IARC_TP53; 23836
DR   Wikidata; Q54972929
RX   PubMed=6144383;
RX   PubMed=6861117;
RX   PubMed=7838528;
RX   PubMed=9283597;
RX   PubMed=9516836;
RX   PubMed=20655465;
RX   PubMed=22213050;
CC   Doubling time: 3 days (PubMed=6861117).
CC   Omics: Transcriptome analysis by microarray.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   3Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 21-03-23; Version: 12
//
RX   PubMed=6144383;
RA   Rupniak H.T., Rein G., Powell J.F., Ryder T.A., Carson S., Povey S.,
RA   Hill B.T.;
RT   "Characteristics of a new human neuroblastoma cell line which
RT   differentiates in response to cyclic adenosine 3':5'-monophosphate.";
RL   Cancer Res. 44:2600-2607(1984).
//
RX   PubMed=6861117; DOI=10.1016/0165-4608(83)90011-0;
RA   Cowell J.K., Rupniak H.T.;
RT   "Chromosome analysis of human neuroblastoma cell line TR14 showing
RT   double minutes and an aberration involving chromosome 1.";
RL   Cancer Genet. Cytogenet. 9:273-280(1983).
//
RX   PubMed=7838528;
RA   Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A.,
RA   Speleman F., Versteeg R.;
RT   "Deletion mapping in neuroblastoma cell lines suggests two distinct
RT   tumor suppressor genes in the 1p35-36 region, only one of which is
RT   associated with N-myc amplification.";
RL   Oncogene 10:291-297(1995).
//
RX   PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7;
RA   Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R.,
RA   De Paepe A., Cremer T., Speleman F.;
RT   "Comparative genomic hybridization analysis of human neuroblastomas:
RT   detection of distal 1p deletions and further molecular genetic
RT   characterization of neuroblastoma cell lines.";
RL   Cancer Genet. Cytogenet. 97:135-142(1997).
//
RX   PubMed=9516836; DOI=10.1016/S0959-8049(97)00319-5;
RA   Van Roy N., Laureys G., Van Gele M., Opdenakker G., Miura R.,
RA   van der Drift P., Chan A., Versteeg R., Speleman F.;
RT   "Analysis of 1;17 translocation breakpoints in neuroblastoma:
RT   implications for mapping of neuroblastoma genes.";
RL   Eur. J. Cancer 33:1974-1978(1997).
//
RX   PubMed=20655465; DOI=10.1016/j.cell.2010.06.004;
RA   Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N.,
RA   Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C.,
RA   Messiaen L.M., Versteeg R., Bernards R.;
RT   "NF1 is a tumor suppressor in neuroblastoma that determines retinoic
RT   acid response and disease outcome.";
RL   Cell 142:218-229(2010).
//
RX   PubMed=22213050; DOI=10.1002/ijc.27415;
RA   Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J.,
RA   Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.;
RT   "PEA15 impairs cell migration and correlates with clinical features
RT   predicting good prognosis in neuroblastoma.";
RL   Int. J. Cancer 131:1556-1568(2012).
//